24 September 2024 Together with fantastic collaborators at the Amsterdam University Medical Center, in particular Jeffrey Umotoy and Steven de Taeye, we have generated a set of new single-domain antibodies against the challenging tetraspannin (4TM domains) CD9 described in this recent publication. The researchers at the AUMC showed that these molecules prevented HIV-1 replication and syncytia formation. The molecules are available at QVQ.
03 July 2024 On Friday July 5th 2024, our CSO Raimond Heukers, will be at the ULLA summerschool in Leiden, to take an international group of pharmaceutical science researchers (MSc, PhD and postdocs) into the wonderful world of single domain antibodies (sdAbs). Raimond’s lecture will cover tips and tricks for the successful development, characterization and utilization of single domain antibodies against GPCRs.
24 June 2024 Our single domain antibodies (sdAbs) Q101c/Q102c detect and inhibit complement factor C5. The two single domain antibodies recently published are available as products Q101c and Q102c. Both sdAbs recognize C5 and its R885H variant and inhibit C5 cleavage, as described in this JBC paper by Eva Struijf et al. sdAbs are availabe as unlabeled reagents or directionally labeled for immediate detection.
24 June 2024 We would like to congratulate our partners from the CanNanoVac consortium, the lab of Joke den Haan, with their latest publication on targeting Siglec1 with sdAb-decorated liposomes. This work not only illustrates the application of sdAbs as targeting ligands on liposomes, it also showcases QVQs ability to generate lead molecules against heavily glycosylated targets. In addition, the paper describes our anti-DC-SIGN product Q94c and anti-HIV gp120 product Q1c. Please visit our product page for more sdAb reagents.
24 June 2024 Looking for something interesting to listen to while you unwind on vacation? Josh Clark and Chuck Bryant of the Stuff You Should Know podcast have you covered! In a recent episode, they delve into the history and funny facts of camelids, with a special focus on llamas.But that’s not all — they also explore the uniqueness of single-domain antibodies (sdAbs) and highlight our broad-neutralizing anti-HIV molecules. It’s a perfect blend of entertainment and education to enjoy while you relax.Our anti-HIV molecules are available on our website!
20 June 2024 Multispectral imaging of 3D patient-derived organoids not only generates beautiful images but also allows for the identification of potential new targets and detection probes to recognize tumor tissue during surgery. This EMBO molecular medicine paper highlights the 3D-imaging capacity of QVQ’s anti-NCAM single domain antibody (sdAb) Q55c, as well as for sdAbs against EGFR and HER2. QVQ offers anti-HER2 (Q17), anti-EGFR (Q44), and other target-specific sdAb probes as unlabeled, cysteine-tagged or directionally labeled reagents.
19 December 2023 Q123, also known as VUN701, a single domain antibody binding human atypical chemokine receptor 3 (aka CXCR7) with nanomolar affinity, is now available for research use. Generated and characterized by Vladimir Bobkov and Martine Smit’s lab at the VU, its effect on receptor conformation was then investigated with Brian Volkman’s lab at Medical College of Wisconsin. Together, this molecule proved to be a neutral antagonist with nanomolar potencies. The work was published in this Science paper last year.
19 November 2024 On November 25th, Stephanie Anbuhl will represent QVQ at the 1st edition of the virtual conference of the GPCR Forum. As one of the invited speakers, Stephanie will present her PhD work on single-domain antibodies targeting the class A GPCR CXCR4. The GPCR forum brings together the global community of GPCR networks. QVQ actively participated as a partner in the Marie Curie International Training Network ONCORNET2.0 focused on the GPCRs CXCR4 and ACKR3.
Kadans Science Partner is happy to welcome a new member to Plus Ultra Utrecht: QVQ. They are the second tenant to sign a lease for the newest life sciences building currently under development on Utrecht Science Park. QVQ is your one-stop shop for affordable high quality single domain antibodies. Their custom projects are tailored to each customer based on a broad range of services, including llama immunization (in collaboration), construction of phage display libraries, custom-tailored selection procedures, production of VHH, plain or equipped with different tags in bacteria and yeast. The QVQ team strives to use its extensive experience to make single domain antibody technology available to the largest possible user base. Close collaborations with top academic research groups and industrial partners ensure … Read more
01 March 2023 On Thursday the 30th of March 2023, our talented early-stage researcher (ESR) within the ITN project ONCORNET2.0, Stephanie Mareike Anbuhl , presented her poster on the reformatting of improved CXCR4-targeting single domain antibodies for biophysical detection methods on the annual meeting of the Medicinal Chemistry & Chemical Biology (MCCB) division of the Royal Netherlands Chemical Society (KNCV) in Lunteren. On her poster, Stephanie illustrated how various immunization and phage display approaches can aid the development of novel CXCR4 binding single domain antibodies against previously untargeted epitopes or conformations and with unprecedented affinity and potency. Also, Stephanie showed examples how such molecules can be developed into higher order multivalent formats for improving potencies even further as well as conjugating … Read more
14 March 2023 In a collaborative project, researchers at QVQ (Stephanie Mareike Anbuhl and Raimond Heukers), VU Amsterdam (Martine Smit lab) and University of Nottingham (Laura Kilpatrick and Steve Hill) have developed a novel approach using labeled VHH to easily assess and quantify binding of ligands to different drug targets. This technology, named NanoB2 (nanobody-NanoBRET), was published in the journal of Cell Reports Methods. The work, driven by Jelle van den Bor and Nick Bergkamp proves again the high potential of labeled VHH as detection agents. In this new technology, labeled VHH are used for the determination of the binding sites, kinetics and affinities of unlabeled drugs and thereby aid the identification of novel ligands. Link
QVQ recently contributed to a study that nicely exemplifies directionally fluorescently labelled single domain antibodies as extracellular receptor conformation sensors. This is a result of a smooth ONCORNET2.0 collaboration, in this case led by Laura Kilpatrick and Steve Hill. Link
Tel: +31(0)30-2533421
info@qvquality.com
Visiting address
Yalelaan 1
Androclus building - 2nd floor
3584 CL Utrecht